Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | PANK3 | Q9H999 | 12/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104337 | 0.87 | RAB9A (0.75) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL4559943 | 0.87 | NPC1 (0.75) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL104605 | 0.84 | NPC1 (0.71) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL7438084 | 0.84 | NPC1 (0.71) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL7437931 | 0.84 | GAA (0.62) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL104586 | 0.83 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL14597010 | 0.83 | NPC1 (0.69) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL14040566 | 0.81 | SMN1; SMN2 (0.63) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL10285113 | 0.81 | SMN1; SMN2 (0.60) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL3151233 | 0.80 | CYP2C9 (0.65) | NPC1RAB9AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301953-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301953-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-8637548-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637548-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7776861-B2 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776861-B2 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2080757-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2009-07-22 | — | — | EP | disclosed |
| EP-1648879-B1 | HETEROARYL-TETRAHYDROPYRIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2008-10-22 | — | — | EP | disclosed |
| EP-1867644-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2007-12-19 | — | — | EP | disclosed |
| WO-2005009988-A1 | HETEROARYL-TETRAHYDROPIPERIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | NPC1 748/4885RAB9A 963/4885MAPT 89/4885 |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | NPC1 748/4885RAB9A 963/4885MAPT 89/4885 |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | NPC1 748/4885RAB9A 963/4885MAPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.